Table 1 Patient characteristics

From: Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial

Characteristic

SIRT plus sorafenib (n = 10)

Median age, years (range)

60 (30–89)

Sex, n (%)

Female

6 (60.0)

Male

4 (40.0)

ECOG PS, n (%)

 0

8 (80.0)

 1

2 (20.0)

 Median time from initial diagnosis to metastatic spread, months (range)

25 (3–133)

Location of metastases, n (%)

 Liver only

7 (70.0)

 Liver and extrahepatic

3 (30.0)

Extent of liver involvementd

 Unilobar

2 (20.0)

 Bilobar

8 (80.0)

 <25%

10 (100.0)

 >25

0

LDH level, n (%)a

 Normal

8 (80.0)

 Elevated

1 (10.0)

Prior treatment, n (%)

 None

8 (80.0)

 Chemotherapyb

1 (10.0)

 Percutaneous ablationc

1 (10.0)

  1. ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, SIRT selective internal radiation therapy.
  2. aLDH level was not available for one patient. bConsisting of adjuvant fotemustine. cAdministered to liver metastases.
  3. dAll patients had total liver involvement of < 25%.
Back to article page